Gerresheimer has reported a 15.7% increase in revenue for the first half of 2025, reaching €1,120.7 million, up from €968.5 million in H1 2024. The rise was driven in part by the 2024 acquisition of Bormioli Pharma, strengthening the company’s position in the pharmaceutical packaging market.
Adjusted EBITDA grew by 11.8% to €210.4 million, despite a challenging market environment. CEO Dietmar Siemssen noted the company’s return to organic growth in Q2 and reaffirmed its strategy of evolving into a system and solution provider, with a focus on biologics and high-value offerings.
The Primary Packaging Glass division contributed €474.9 million in revenue, up 11.3% from the previous year. This growth stemmed largely from Bormioli Pharma’s integration. However, on an organic basis, revenue declined 7.6%, impacted by reduced demand in the cosmetics sector and for oral liquid containment solutions. These declines are expected to be temporary.
Adjusted EBITDA in the glass division rose 14.7% to €85.2 million, with the EBITDA margin improving to 17.9% due to a greater share of high-value products like ready-to-fill injection vials. 
Looking ahead, Gerresheimer anticipates stronger performance in the second half of 2025. Growth will be driven by new production lines for medical devices, an expanded biologics-focused portfolio, and the return to full operations at its Lohr, Germany, and Morganton, USA, facilities. The company remains confident in outperforming market growth in the medium to long term.
Source: Gerresheimer with additional information added by Glass Balkan
